Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Bergmann NC, Lund A, Gasbjerg LS, et al
Lexology / Reed Smith
The current FDA status of BPC-157 is that of an unapproved drug compound with no active Investigational New Drug (IND) application accepted for human clinical trials as of available records
KEY DETAILS Program starts July 1, 2026 Flat $50 patient copay No deductible Only 28- or 30-day fills A new PA is required when switching medications Prescribers do not need to be enrolled in Medicare, but cannot be on the CMS Preclusion List Please share this with prescribers, pharmacists, nurses, medical assistants, and prior authorization teams
The research also highlighted a significant reduction in deep abdominal visceral fatthe type of stubborn fat linked to metabolic issues that often resists traditional diet and exercise
